Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.

Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.

Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.

Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.

Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.

Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.

Risperidone LAI injections will be administered will be administered per the locally approved label indications.